Luke Maese, DO - Applying Therapeutic Innovations Against ALL: From Updated Evidence to Everyday Practice

Go online to PeerView.com/DGJ860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. Are you up to date on recent evidence on acute
lymphoblastic leukemia (ALL) emerging from major scientific
congresses? In this activity, an ALL specialist explores recent
evidence presented at the 2022 American Society of Clinical
Oncology (ASCO) and European Hematology Association (EHA) annual
meetings on developments in various treatment modalities for ALL.
Watch this video to hear about the latest evidence and practical
applications in asparaginase use in chemotherapy protocols,
including important dosing and safety data on recombinant Erwinia;
get updated on longer-term outcomes with CAR-T therapy in adult and
pediatric patients and hear practical considerations when using
CAR-T options; and learn about emerging chemo-sparing TKI plus
bispecific combinations in Ph-positive ALL. Upon completion of this
activity, participants should be better able to: Summarize new
evidence on multi-faceted strategies for ALL management based on
modern chemotherapy protocols, antibody-based approaches, cellular
therapy, and TKIs; Cite evidence supporting the use of novel
asparaginase compounds for ALL in the context of asparaginase
toxicity/hypersensitivity, including in pediatric, AYA, and adult
populations; and Apply new science to the team-based management of
ALL, including when managing asparaginase hypersensitivity or
toxicity, developing TKI-based protocols in Ph-positive disease, or
when utilizing novel immunotherapy-based approaches in patient
care.